West African Emerging Infectious Disease Research Center (WA-EIDRC)

项目摘要 随着急性SARS-CoV-2感染口服抗病毒治疗的使用越来越多， 已多次报告的症状和病毒载量反弹后，规定 疗程最常用的口服抗病毒药物是帕昔洛韦，虽然它已成为一种 测试到治疗计划的组成部分，没有发病率或患病率数字， 5天疗程后，Paxlovid（肿瘤学和/或病毒学）反弹。 此外，症状、病毒载量反弹和免疫相关性之间的联系是 也是未知的。从公共卫生的角度来看，这是最紧迫的，因为 尽管进行了Paxlovid治疗，个体仍有可能保持感染性， 关于抗药性的潜在发展。因此，通过额外的资金，我们 建议研究发病率、流行率、传染病学、病毒进化和免疫 在完成Paxlovid治疗后反弹的COVID-19病例的相关性。

PROJECT SUMMARY With the increasing use of oral antiviral treatments for acute SARS-CoV-2 infection, there have been multiple reports of symptom and viral load rebound after the prescribed treatment course. The most prescribed oral antiviral is Paxlovid, and while it has become a component of test-to-treat programs, there are no incidence or prevalence numbers on Paxlovid (symptomatologic and/or virologic) rebound after the five-day treatment course. Further, the connection between symptoms, viral load rebound, and immune correlates is unknown as well. This is of utmost urgence from a public health standpoint, given the possibility of the individual remaining infectious despite Paxlovid treatment and concerns about the potential development of drug resistance. Therefore, with additional funding we propose to study the incidence, prevalence, symptomatology, virus evolution, and immune correlates of COVID-19 cases who rebound after completion of Paxlovid treatment.